A retrospective, comparative efficacy study between initial 3-monthly intravitreal conbercept monotherapy and combination intravitreal conbercept with photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV)
Latest Information Update: 23 Feb 2021
Price :
$35 *
At a glance
- Drugs Conbercept (Primary)
- Indications Polypoidal choroidal vasculopathy
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2021 New trial record